Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Infection of the biliary passages with clonorchis sinensis, also called Opisthorchis sinensis. It may lead to inflammation of the biliary tract, proliferation of biliary epithelium, progressive portal fibrosis, and sometimes bile duct carcinoma. Extension to the liver may lead to fatty changes and cirrhosis. (From Dorland, 27th ed)
Biomarker and diagnostic research for clonorchiasis has been reported in the published literature.
1 FDA-approved treatment is available for clonorchiasis, including PRAZIQUANTEL (BILTRICIDE, approved 1982).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
1 clinical trial registered, 1 recruiting. Interventions under study include drug therapy. Pipeline includes 1 PHASE4. Research is primarily sponsored by academic and government institutions.
108 publications have been identified in PubMed for clonorchiasis. Research spans Basic Science / Preclinical (44%), Epidemiology / Natural History (22%), and Case Report / Case Series (11%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 47 | 44% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 12:48 AM UTC
European rare disease database
Common questions about clonorchiasis
PRAZIQUANTEL |
— |
1982 |
Discontinued |
Gene therapy approaches for clonorchiasis have been reported in the published literature.
1 trial found
Disease patterns and progression |
24 |
22% |
Patient case studies | 12 | 11% |
Testing and diagnosis research | 9 | 8% |
Research summaries | 7 | 6% |
Clinical study results | 5 | 5% |
New treatment approaches | 3 | 3% |
Other research | 1 | 1% |
Ma X (2026). [PMID: 41973752](https://pubmed.ncbi.nlm.nih.gov/41973752/). *PLoS Negl Trop Dis*. [Diagnostic / Biomarker]
Tobin EH (2026). [PMID: 30422487](https://pubmed.ncbi.nlm.nih.gov/30422487/). *Unknown Journal*. [Review / Meta-Analysis]
Huang C (2026). [PMID: 41919759](https://pubmed.ncbi.nlm.nih.gov/41919759/). *Parasite*. [Review / Meta-Analysis]
Kim SH (2026). [PMID: 41596332](https://pubmed.ncbi.nlm.nih.gov/41596332/). *International journal of molecular sciences*. [Basic Science / Preclinical]
Zhou L (2026). [PMID: 41685322](https://pubmed.ncbi.nlm.nih.gov/41685322/). *Frontiers in immunology*. [Basic Science / Preclinical]
Srivastava B (2026). [PMID: 41670675](https://pubmed.ncbi.nlm.nih.gov/41670675/). *Abdominal radiology (New York)*. [Epidemiology / Natural History]
Nakano M (2026). [PMID: 41263943](https://pubmed.ncbi.nlm.nih.gov/41263943/). *Clinical journal of gastroenterology*. [Basic Science / Preclinical]
Zhao Z (2026). [PMID: 40669598](https://pubmed.ncbi.nlm.nih.gov/40669598/). *Journal of advanced research*. [Epidemiology / Natural History]
Wei S (2026). [PMID: 42042964](https://pubmed.ncbi.nlm.nih.gov/42042964/). *Trop Med Infect Dis*. [Diagnostic / Biomarker]
Ji T (2026). [PMID: 42157131](https://pubmed.ncbi.nlm.nih.gov/42157131/). *BMC Infect Dis*. [Case Report / Case Series]